Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 65Kidney Neoplasms 18Neoplasms 16Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma 8Melanoma 7Glioblastoma 5Clear-cell metastatic renal cell carcinoma 5Lung Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Ovarian Neoplasms 3Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraganglioma 2Liver Neoplasms 2Kidney Diseases 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Axitinib × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡